In a significant development for the Indian pharmaceutical sector, the United States has announced a zero-tariff policy for specific specialty drugs and their associated ingredients imported from India. This exemption, also extended to 19 other jurisdictions, offers a crucial relief for exporters dealing with treatments for rare medical conditions.
Zero Tariffs for Key Specialty Medicines
The US Commerce Department's notice specifies that the zero-tariff category encompasses a range of critical medicines. These include all drugs designated for orphan diseases, infertility treatments, advanced cell and gene therapies, antibody-drug conjugates, and animal pharmaceuticals. Components of these drugs are also eligible for the zero-tariff rate, focusing on specialty medicines rather than the broader pharmaceutical trade. The exemption also covers nuclear medicines, plasma-derived therapies, and certain medical countermeasures against chemical, biological, radiological, and nuclear threats.
Context: 100% Tariffs on Other Patented Drugs
This relief comes amidst a broader US policy shift. Washington is simultaneously preparing to impose a 100 percent tariff on certain patented pharmaceutical imports and their associated ingredients, effective from September 29. These tariffs, enacted under President Donald Trump’s April 2 proclamation, aim to encourage domestic production. However, it is crucial to note that generic pharmaceutical products and their associated ingredients are explicitly not subject to these Section 232 pharmaceutical tariffs, a distinction particularly significant for India, a major exporter of generic medicines.
India Among 20 Beneficiary Nations
India joins a list of 20 countries and jurisdictions benefiting from this zero-tariff provision. Other nations include Argentina, Bangladesh, the European Union, Japan, South Korea, Switzerland, and the United Kingdom. The Commerce Department explained that these jurisdictions qualify due to existing or forthcoming trade and security framework agreements with the US, or because their products meet an urgent US health need.
Process for Tariff Relief
The Commerce Department has also established a formal process for companies to seek tariff relief for specialty pharmaceutical products that address an urgent US health need. Applications must detail the product's classification, active ingredients, manufacturer, country of origin, and the specific medical need it addresses. These requests will be reviewed on a case-by-case basis in consultation with the US Trade Representative and the Department of Health and Human Services. Additionally, a zero-tariff provision has been added for certain products imported solely for clinical trials, research and development, or other non-commercial purposes.